McInnes, Iain B.
Byers, Nicole L.
Higgs, Richard E.
Lee, Jonathan
Macias, William L.
Na, Songqing
Ortmann, Robert A.
Rocha, Guilherme
Rooney, Terence P.
Wehrman, Thomas
Zhang, Xin
Zuckerman, Steven H.
Taylor, Peter C.
Funding for this research was provided by:
Eli Lilly and Company
Incyte Corporation
Article History
Received: 17 December 2018
Accepted: 22 July 2019
First Online: 2 August 2019
Ethics approval and consent to participate
: Whole blood samples from healthy volunteers were obtained under a protocol approved by the Institutional Review Board of Stanford University (reference numbers 5136 and 6208). The IRB provided a Waiver of Consent because leukocyte-enriched fractions are by-products of the blood donation.
: Not applicable.
: IBM has received grants and personal fees from AbbVie, Eli Lilly and Company, Janssen, Novartis, Pfizer, and Roche. NLB, REH, WLM, SN, RAO, GR, TPR, XZ, and SHZ are employees and shareholders of Eli Lilly and Company. JL was an employee and shareholder of Eli Lilly and Company when contributions to this article were made. He is now an employee of PDD4Patients LLC. TW is an employee and shareholder of Primity Bio. PCT has received grants and personal fees from Eli Lilly and Company, Galapagos, and UCB. He has received grants from Abide Therapeutics and Celgene and personal fees from AbbVie, Biogen, GSK, Janssen, Novartis, Pfizer, and Sandoz.